secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001701541-23-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics reports Q4 net loss $21.1M; cash $122.8M; BDTX-1535 update H2 2023
--------------------------------------------------------------------------------

- Net loss $21.1M in Q4 2022, full year net loss $91.2M (vs $125.6M in 2021).
- Cash, cash equivalents and investments $122.8M as of Dec 31, 2022; sufficient into Q3 2024.
- Phase 1 update for EGFR inhibitor BDTX-1535 expected H2 2023; trial actively recruiting.
- FDA cleared IND for BRAF/RAS inhibitor BDTX-4933; Phase 1 start expected H1 2023.
- Spinout of Launchpad Therapeutics with $30M Series A led by Versant and NEA; BDTX retains minority stake.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154123000018/0001701541-23-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154123000018/bdtx-20230309.htm
  HTML page:      https://secwatch.observer/filing/0001701541-23-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer